China’s NMPA Accepts Clinical Trial Application for Harbour BioMed’s Obesity Antibody LET003

20 November 2026 | Friday | News


Developed using Harbour BioMed’s Hu-mAtrIx™ AI platform, LET003 targets the activin receptors ACVR2A and ACVR2B. In preclinical studies, adding the antibody to semaglutide increased fat loss while preserving lean mass.

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, announced that the National Medical Products Administration (NMPA) of China has accepted the Investigational New Drug (IND) application for LET003, its first next-generation ACVR2A/2B-targeting monoclonal antibody developed using the Hu-mAtrIx™ AI platform, for the treatment of overweight or obesity.

 

Obesity is a chronic, complex disease associated with an increased risk of numerous serious health conditions, including type 2 diabetes, cardiovascular disease and certain cancers. While GLP-1-based therapies have transformed obesity management by enabling substantial weight loss, the accompanying loss of lean mass remains a major challenge in optimizing body composition and long-term treatment outcomes. Targeting activin receptors ACVR2A and ACVR2B, which play key roles in regulating muscle and fat homeostasis, represents a promising therapeutic approach to enhancing fat reduction while preserving or improving lean mass, particularly in combination with existing weight-loss therapies.

LET003 is Harbour BioMed's first AI-enabled drug candidate, designed as a dual ACVR2A/ACVR2B blocker to target these receptors. In preclinical studies, LET003 exhibited superior pharmacokinetic characteristics compared to multiple competitor molecules. When combined with semaglutide, LET003 significantly enhanced fat reduction while effectively preserving lean mass. In addition, LET003 achieved lean mass-promoting effects at lower dose level comparable to bimagrumab at higher dose level, highlighting its potential to become a best-in-class therapy for overweight or obesity treatment.

"NMPA's acceptance of the IND application for LET003 marks a significant milestone for Harbour BioMed. LET003 leads the exciting progress in our obesity portfolio in addition to being our first AI-enabled candidate developed using our proprietary Hu-mAtrIx™ platform," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "We look forward to advancing LET003 through clinical development and further realizing the potential of our AI-enabled drug discovery capabilities to address significant unmet medical needs."

"Obesity treatment is evolving beyond weight reduction alone toward improving body composition and achieving more sustainable health outcomes," said Dr. Bob Zhang, President of the Metabolic Disease Franchise at Harbour BioMed. "By targeting ACVR2A and ACVR2B, LET003 is designed to address an important challenge in overweight or obesity management: preserving or improving lean mass while enhancing fat reduction. We believe LET003 has the potential to offer a differentiated therapeutic approach and look forward to evaluating its potential in clinical development."

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close